Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|28|2914-2931

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.28, 2008-10, pp. : 2914-2931

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET

By  

Current Pharmaceutical Design, Vol. 7, Iss. 18, 2001-12 ,pp. : 1863-1892

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography

By  

Current Pharmaceutical Design, Vol. 9, Iss. 11, 2003-04 ,pp. : 931-944

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Radiolabelled Anticancer Drugs for Positron Emission Tomography

By  

Current Pharmaceutical Design, Vol. 9, Iss. 11, 2003-04 ,pp. : 917-929

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs

By Elie Valery   de Beaumais Tiphaine   Fakhoury May   Jacqz-Aigrain Evelyne  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 827-843

Future Medicine

Access to resources Recommend Favorite

Chemogenomics of Sensitivity and Resistance to Anticancer Drugs

By  

Current Pharmacogenomics, Vol. 5, Iss. 1, 2007-03 ,pp. : 11-19

Bentham Science Publishers

Access to resources Recommend Favorite